Stock Events

Stock Events

Acorda Therapeutics 

€9.36
0
+€0.00+0% Tuesday 20:00

Statistics

Day High
-
Day Low
-
52W High
9.36
52W Low
9.36
Volume
-
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CDG.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap31.91B
Biogen offers multiple sclerosis (MS) treatments, directly competing with Acorda's MS therapies.
Novartis
NVS
Mkt Cap305.1B
Novartis provides a range of MS treatments, including oral and infusion therapies, competing in the same space as Acorda.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap40.34B
Teva Pharmaceutical has a strong presence in the MS market with Copaxone, directly competing with Acorda's offerings.
Roche
RHHBY
Mkt Cap341.62B
Roche, with its MS drug Ocrevus, competes in the neurology space, targeting a similar patient group as Acorda.
Gilead Sciences
GILD
Mkt Cap162.98B
Gilead Sciences, though more known for its HIV and hepatitis C drugs, is expanding into other areas, including potential treatments that could compete with Acorda's neurological therapies.
Pfizer
PFE
Mkt Cap138.61B
Pfizer has a broad portfolio that includes treatments for neurological disorders, potentially competing with Acorda's products.
Merck
MRK
Mkt Cap319.99B
Merck has been expanding its focus on neurodegenerative diseases, including MS, which could position it as a competitor to Acorda.
Alkermes
ALKS
Mkt Cap9.19B
Alkermes focuses on central nervous system (CNS) disorders, with a portfolio that could compete with Acorda's neurological therapies.
Astrazeneca
AZN
Mkt Cap302.65B
AstraZeneca, with its broad research in various therapeutic areas, including neurology, could become a competitor as it expands its portfolio.

About

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Show more...
CEO
Ron Cohen
Employees
111
Country
United States
ISIN
US00484M1062

Listings

STU
DE
CDG.STU

0 Comments

Share your thoughts

FAQ

What is Acorda Therapeutics stock price today?▼
The current price of CDG.STU is €9.36 EUR — it has increased by +0% in the past 24 hours. Watch Acorda Therapeutics stock price performance more closely on the chart.
What is Acorda Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Acorda Therapeutics stocks are traded under the ticker CDG.STU.
How many employees does Acorda Therapeutics have?▼
As of July 10, 2026, the company has 111 employees.
In which sector is Acorda Therapeutics located?▼
Acorda Therapeutics operates in the Manufacturing sector.
When did Acorda Therapeutics complete a stock split?▼
Acorda Therapeutics has not had any recent stock splits.
Where is Acorda Therapeutics headquartered?▼
Acorda Therapeutics is headquartered in Ardsley, United States.